Carl Gordon

BLSM Director Carl Gordon Buys $10M in Open-Market Purchase

by
SEC Form 4 filing document showing an insider stock purchase disclosure for BlossomHill Therapeutics

A fresh Form 4 filing shows Carl L. Gordon, a director of BlossomHill Therapeutics, Inc. (BLSM), purchased 625,000 shares of the company on the open market on August 10, 2026. The transaction, priced at $16.00 per share, totaled $10,000,000.00 — a purchase made with the insider’s own funds rather than acquired through options or other … Read more

Scribe Therapeutics Director Gordon Buys $15M in SCTX Stock

by
SEC Form 4 filing details showing Carl L. Gordon's $15 million insider stock purchase in Scribe Therapeutics

Carl L. Gordon, a director at Scribe Therapeutics, Inc. (SCTX), disclosed an open-market purchase of 1,000,000 shares at $15.00 per share, a bet worth exactly $15,000,000.00, according to a Form 4 filed with the SEC. The transaction is dated July 27, 2026. Following the purchase, Gordon’s stake stands at 1,348,825 shares, held indirectly through a … Read more